Noile-Immune Biotech Inc. (TYO:4893)
Japan
· Delayed Price · Currency is JPY 169.00
+2.00 (1.20%)
Jun 27, 2025, 3:30 PM JST
Noile-Immune Biotech Revenue
Noile-Immune Biotech had revenue of 2.00M JPY in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to 7.00M, down -97.74% year-over-year. In the year 2024, Noile-Immune Biotech had annual revenue of 7.00M, down -97.78%.
Revenue
7.00M
Revenue Growth
-97.74%
P/S Ratio
1,045.43
Revenue / Employee
280.00K
Employees
25
Market Cap
7.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | -309.00M | -97.78% |
| Dec 31, 2023 | 316.00M | -309.00M | -49.44% |
| Dec 31, 2022 | 625.00M | 525.00M | 525.00% |
| Dec 31, 2021 | 100.00M | 3.00M | 3.09% |
| Dec 31, 2020 | 97.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Takeda Pharmaceutical Company | 4,581.55B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 866.03B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Shionogi & | 438.27B |